中国现代医生2024，Vol.62Issue(1)：22-27,6.DOI:10.3969/j.issn.1673-9701.2024.01.006
酪氨酸激酶抑制剂对放射性碘难治性分化型甲状腺癌疗效的Meta分析
Meta-analysis of the efficacy of tyrosine kinase inhibitor in radioiodine-refractory differentiated thyroid carcinoma
摘要
Abstract
Objective To investigate the effect of tyrosine kinase inhibitor(TKI)on radioiodine-refractory differentiated thyroid carcinoma(RAI-rDTC).Methods Literature related to RAI-rDTC was retrieved from Wanfang Data,CNKI,VIP,PubMed,Cochrane,EmBase and Medline databases until December 31,2021.Literature quality and experimental bias were referred to the Cochrane quality risk assessment table,and Meta-analysis was performed using RevMan 5.3 software.Results A total of 1384 patients were included in 6 studies.The results of Meta-analysis showed that the median progress free survive(HR=0.30,95%CI:0.18-0.50,P<0.00001)and overall survival(HR=0.70,95%CI:0.57-0.88,P=0.002)in treatment group were significantly longer than those in control group.There was no significant difference in complete response between two groups(RR=3.31,95%CI:0.41-26.89,P=0.26).The partial response in treatment group was significantly higher than that in control group(RR=15.97,95%CI:3.48-73.17,P=0.0004).The incidence of TKI-related adverse reactions above grade 3 in treatment group was significantly higher than that in control group(RR=2.91,95%CI:1.70-4.96,P<0.0001).Conclusion TKI can significantly prolong progress free survive and overall survival in patients with RAI-rDTC,but there are still many adverse reactions.It is necessary to comprehensively evaluate the health status of patients before medication.关键词
酪氨酸激酶抑制剂/放射性碘难治性分化型甲状腺癌/疗效/不良事件/Meta分析Key words
Tyrosine kinase inhibitor/Radioiodine-refractory differentiated thyroid carcinoma/Efficacy/Adverse events/Meta-analysis分类
临床医学引用本文复制引用
倪萃,苏景阳,林胜友..酪氨酸激酶抑制剂对放射性碘难治性分化型甲状腺癌疗效的Meta分析[J].中国现代医生,2024,62(1):22-27,6.基金项目
浙江省名老中医专家传承工作室建设项目(GZS202002) （GZS202002）
